INTS

Intensity Therapeutics, Inc. - Common Stock (INTS)

About Intensity Therapeutics, Inc. - Common Stock (INTS)

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.

Details

Daily high

$4.08

Daily low

$3.85

Price at open

$3.96

52 Week High

$43.50

52 Week Low

$3.51

Market cap

10.6M

Dividend yield

0.00%

Volume

72,994

Avg. volume

35,272

P/E ratio

-.56

Intensity Therapeutics, Inc. - Common Stock News